Epirubicin and ifosfamide in advanced soft tissue-sarcomas

S. Frustaci, S. Foladore, A. Buonadonna, A. De Paoli, D. Crivellari, A. Carbone, R. Sorio, S. Morassut, S. Monfardini

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients. Patients and methods: Treatment consisted of: epirubicin 75 mg/m 2 i.v. day 1; IFO 1.8 g/m 2 days 1 to 5; MESNA 20% of the IFO dose at 4-hour intervals three times a day during IFO administration. Cycles were given every 3-4 weeks for at least three cycles. Results: The overall response rate for non-visceral sarcomas (51 pts) ws 31% (95% confidence limits ± 13%). Among the 13 visceral sarcomas no response was seen for the leiomyosarcomas of the gastrointestinal tract, whereas one complete and one partial remission were observed for the uterine sarcomas. The duration of response was 10 months (range 5-34+) for complete responses and 9 (range 4-42+) for partial responses. The median survival for responders is 18 months (range 2-60+) and for non-responders 10 months (range 1-33) (p <0.004). Conclusions: This combination proved to be feasible and tolerable. The overall response rate does not appear to be superior to those with other standard treatments, but it should be pointed out that our patient population was totally unselected.

Original languageEnglish
Pages (from-to)669-672
Number of pages4
JournalAnnals of Oncology
Volume4
Issue number8
Publication statusPublished - 1993

Fingerprint

Epirubicin
Ifosfamide
Sarcoma
Leiomyosarcoma
Gastrointestinal Tract
Survival
Therapeutics
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Frustaci, S., Foladore, S., Buonadonna, A., De Paoli, A., Crivellari, D., Carbone, A., ... Monfardini, S. (1993). Epirubicin and ifosfamide in advanced soft tissue-sarcomas. Annals of Oncology, 4(8), 669-672.

Epirubicin and ifosfamide in advanced soft tissue-sarcomas. / Frustaci, S.; Foladore, S.; Buonadonna, A.; De Paoli, A.; Crivellari, D.; Carbone, A.; Sorio, R.; Morassut, S.; Monfardini, S.

In: Annals of Oncology, Vol. 4, No. 8, 1993, p. 669-672.

Research output: Contribution to journalArticle

Frustaci, S, Foladore, S, Buonadonna, A, De Paoli, A, Crivellari, D, Carbone, A, Sorio, R, Morassut, S & Monfardini, S 1993, 'Epirubicin and ifosfamide in advanced soft tissue-sarcomas', Annals of Oncology, vol. 4, no. 8, pp. 669-672.
Frustaci S, Foladore S, Buonadonna A, De Paoli A, Crivellari D, Carbone A et al. Epirubicin and ifosfamide in advanced soft tissue-sarcomas. Annals of Oncology. 1993;4(8):669-672.
Frustaci, S. ; Foladore, S. ; Buonadonna, A. ; De Paoli, A. ; Crivellari, D. ; Carbone, A. ; Sorio, R. ; Morassut, S. ; Monfardini, S. / Epirubicin and ifosfamide in advanced soft tissue-sarcomas. In: Annals of Oncology. 1993 ; Vol. 4, No. 8. pp. 669-672.
@article{98b9fdc2037244e59d1a989aca8c22b6,
title = "Epirubicin and ifosfamide in advanced soft tissue-sarcomas",
abstract = "Background: To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients. Patients and methods: Treatment consisted of: epirubicin 75 mg/m 2 i.v. day 1; IFO 1.8 g/m 2 days 1 to 5; MESNA 20{\%} of the IFO dose at 4-hour intervals three times a day during IFO administration. Cycles were given every 3-4 weeks for at least three cycles. Results: The overall response rate for non-visceral sarcomas (51 pts) ws 31{\%} (95{\%} confidence limits ± 13{\%}). Among the 13 visceral sarcomas no response was seen for the leiomyosarcomas of the gastrointestinal tract, whereas one complete and one partial remission were observed for the uterine sarcomas. The duration of response was 10 months (range 5-34+) for complete responses and 9 (range 4-42+) for partial responses. The median survival for responders is 18 months (range 2-60+) and for non-responders 10 months (range 1-33) (p <0.004). Conclusions: This combination proved to be feasible and tolerable. The overall response rate does not appear to be superior to those with other standard treatments, but it should be pointed out that our patient population was totally unselected.",
author = "S. Frustaci and S. Foladore and A. Buonadonna and {De Paoli}, A. and D. Crivellari and A. Carbone and R. Sorio and S. Morassut and S. Monfardini",
year = "1993",
language = "English",
volume = "4",
pages = "669--672",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "8",

}

TY - JOUR

T1 - Epirubicin and ifosfamide in advanced soft tissue-sarcomas

AU - Frustaci, S.

AU - Foladore, S.

AU - Buonadonna, A.

AU - De Paoli, A.

AU - Crivellari, D.

AU - Carbone, A.

AU - Sorio, R.

AU - Morassut, S.

AU - Monfardini, S.

PY - 1993

Y1 - 1993

N2 - Background: To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients. Patients and methods: Treatment consisted of: epirubicin 75 mg/m 2 i.v. day 1; IFO 1.8 g/m 2 days 1 to 5; MESNA 20% of the IFO dose at 4-hour intervals three times a day during IFO administration. Cycles were given every 3-4 weeks for at least three cycles. Results: The overall response rate for non-visceral sarcomas (51 pts) ws 31% (95% confidence limits ± 13%). Among the 13 visceral sarcomas no response was seen for the leiomyosarcomas of the gastrointestinal tract, whereas one complete and one partial remission were observed for the uterine sarcomas. The duration of response was 10 months (range 5-34+) for complete responses and 9 (range 4-42+) for partial responses. The median survival for responders is 18 months (range 2-60+) and for non-responders 10 months (range 1-33) (p <0.004). Conclusions: This combination proved to be feasible and tolerable. The overall response rate does not appear to be superior to those with other standard treatments, but it should be pointed out that our patient population was totally unselected.

AB - Background: To evaluate the feasibility, toxicity and efficacy of the combination of (IFO) ifosfamide and epirubicin (EPI) given at conventional doses for monochemotherapy, we started a phase II study in advanced/metastatic soft tissue sarcoma patients. Patients and methods: Treatment consisted of: epirubicin 75 mg/m 2 i.v. day 1; IFO 1.8 g/m 2 days 1 to 5; MESNA 20% of the IFO dose at 4-hour intervals three times a day during IFO administration. Cycles were given every 3-4 weeks for at least three cycles. Results: The overall response rate for non-visceral sarcomas (51 pts) ws 31% (95% confidence limits ± 13%). Among the 13 visceral sarcomas no response was seen for the leiomyosarcomas of the gastrointestinal tract, whereas one complete and one partial remission were observed for the uterine sarcomas. The duration of response was 10 months (range 5-34+) for complete responses and 9 (range 4-42+) for partial responses. The median survival for responders is 18 months (range 2-60+) and for non-responders 10 months (range 1-33) (p <0.004). Conclusions: This combination proved to be feasible and tolerable. The overall response rate does not appear to be superior to those with other standard treatments, but it should be pointed out that our patient population was totally unselected.

UR - http://www.scopus.com/inward/record.url?scp=0027383660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027383660&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 669

EP - 672

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 8

ER -